Difficult SLE skin dse? Dr. Mosca reminds us to engage pts in the treatment process including adherence to preventive measures & lifestyle mods (sun protection, smoking) Other considerations: + antimalarials early use of newer tx? - Anifrolumab #ACR23 @RheumNow https://t.co/kz8YfcBB2d

Frailty in PMR @DrTrishHarkins >1/3 are frail or pre-frail. Frailty correlates with PROs - worse mood, pain, fatigue, and QoL. Abstr#1201 #ACR23 @RheumNow https://t.co/pH5yG4AscU https://t.co/QuHmOgpLbi

Telemedicine tools with central evaluation of clinical and imaging (+/- MRI SIJs) information may be helpful in the diagnostic process for patients with suspected axSpA. This reduces the risk of overdiagnosis, Poddubnyy D, Abst#1392 #ACR23 @RheumNow https://t.co/kYEMdqmQF8 https://t.co/2lRg2byGjK

Pooled safety analysis of 48 phase II/III/IV trials on secukinumab for tx of PsO, PsA and axSpA Well tolerated No new long term safety signals IBD, malginancy, MACE remain low @RheumNow #ACR23 Abs#1436 https://t.co/6dzdO5Vpuc

The Great Debate #ACR23 - and it’s a cracker. Is early steroid-sparing therapy justified in GCA/PMR? I don’t know, but Rob Spiera and @philseo will battle it out to tell us. (and ably moderated by the always eloquent @SattuiSEMD) I’ll put some highlights here ⬇️🧵 @RheumNow https://t.co/ASpuglyENv

Should #filgo be fil-gone in North America? Unfortunately #filgotinib is not in NA, but is elsewhere & expanding into other diseases #IBD, IA, etc. Safety at >8yrs is similar to other #JAKi. #CDAI in MTX-IR at 1 yr in 200mg is impressive. @ACRheum @RheumNow #ACR23 1323, 1325 https://t.co/3iAZRcSeq6

Baseline vascular ultrasound predicts clinical outcomes @ 3 months. Subclinical GCA = relapse 37% vs 15%. Higher cumulative steroid dose. @sharoncowley01 @DrTrishHarkins Abstr#1565 #ACR23 @RheumNow https://t.co/b35CkFS0lz https://t.co/suBGR1ByDK

So firstly the no case, and Rob Spiera takes up the case, dictated by the electronic coin toss. No-one disagrees that we need steroid-sparing options, or that IL-6Ri work in PMR and GCA. But it’s the strategy questions which remain in play: #ACR23 @RheumNow https://t.co/I2QDU7l6DE

@RheumNow #ACR23 #GreatDebate Use Advanced Rx for GCA 1st line? Spiera: No No ev for disease modification with early Rx Lose only reliable biomark of dis activity w IL-6 inhib No evid of reduced major GC AEs $$ GCA: treat by GC alone, taper off by 6 m, low threshold to escal https://t.co/QxgAlVKitd

@RheumNow So what might early steroid-sparing therapy in PMR/GCA achieve? Cure? Superior disease activity control? Minimize damage? Improve QoL/function? Well, sadly we have a long way to go in defining a lot of this: #ACR23 @RheumNow https://t.co/QeidAHHm8x